Navigation Links
Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R)
Date:10/6/2008

ries of studies was conducted to validate this approach.

-- Relative bioavailability was assessed in 40 patients randomized to naltrexone SR 40mg or naltrexone immediate release (IR) 36mg in a single dose, crossover PK assessment. Analyses revealed that, on a dose-normalized basis, naltrexone SR was associated with a 43.3% lower peak concentration but a comparable exposure or area-under-the-curve (AUC) to the IR formulation. The Tmax or time to peak concentration was approximately 36 minutes slower for naltrexone SR compared to naltrexone IR.

-- Preliminary evidence for improved tolerability with naltrexone SR came from a trial utilizing a multiple dose, parallel design in 60 healthy volunteers randomized to either naltrexone SR 37.5mg / bupropion SR 270mg or naltrexone IR 36mg / bupropion SR 270mg. Patients were treated for up to 14 days. Naltrexone SR / bupropion SR patients spontaneously reported fewer GI adverse events (10.3% vs. 16.7%) or CNS adverse events (10.3% vs. 23.3%). GI event severity was also subjectively lowered with the naltrexone SR formulation.

-- In a preliminary effort to evaluate apparent improvements in tolerability associated with naltrexone SR, pooled 24 week data from the Phase 2 NB-201 Contrave trial (N=212) with naltrexone IR was compared with the 24 week blinded data from a series of four Phase 3 Contrave trials (N=3,943 evaluable patients), all employing naltrexone SR. These Phase 3 trials all have varying designs, doses and patient populations; the discontinuation due to adverse event rates associated with them ranged from 13.8% to 22.8%. However, compared to the Phase 2 trial experience, lower rates of nausea were evident across the four pooled Phase 3 trials. In study NB-301 (N=1,689 evaluable patients), the trial with dosing most similar to the Phase 2 NB-201 trial, nausea, headache, or dizziness were all less frequent than in the prior Phase 2 trial, as was the overall rate of early discontinuation due to any a
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Orexigen(R) Initiates Second Phase IIb Empatic(TM) Trial on Schedule
2. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
3. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
4. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
5. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
6. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
7. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
8. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
9. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
10. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
11. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... As health officials across the Midwest warn against the widespread ... Michigan will offer free diagnostic testing for ... to administer tests and, in some cases, fill the matching ... the study. The Grand Rapids, Mich. ...
(Date:1/15/2014)... Jan. 15, 2014 Massachusetts General Hospital (MGH), ... AMGN ) announced today that they have launched ... new therapeutic targets and develop novel therapies for ... affects millions worldwide. The MGH-Broad-Amgen collaboration brings together ...
(Date:1/15/2014)... LOUISVILLE, Ky. , Jan. 15, 2014  Manufacturers, ... technologies must be able to protect their most ... (Logo: http://photos.prnewswire.com/prnh/20130716/CL46586LOGO ) Because ... Industry, it steadfastly remains one of the most ...
Breaking Medicine Technology:Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 2Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Intellectual Property Insurance for Medical-related Products and Services 2
... April 14, 2011 Attorney General Roy Cooper warned ... that a measure giving immunity to pharmaceutical companies could ... "hundreds of millions of dollars." Still, the ... controversial measure.  HB 542 could go to the House ...
... ANN ARBOR, Mich., April 14, 2011 Adeona Pharmaceuticals, ... innovative medicines for serious central nervous system diseases, announced ... to discuss the results from the clinical study evaluating ... disease and mild cognitive impairment on Friday, April 15, ...
Cached Medicine Technology:GOP's Big Pharma Protection to Cost NC Taxpayers "Hundreds of Millions" 2Adeona to Host Conference Call 2
(Date:4/18/2014)... Fraser University psychologists have made a brain-related discovery ... attention-deficit disorders. , This discovery opens up the ... or suppress a specific brain activity that the ... , The Journal of Neuroscience has ... John McDonald, an associate professor of psychology and ...
(Date:4/17/2014)... chronic inflammation in non-cancerous prostate tissue may have nearly ... those with no inflammation, according to results of a ... Kimmel Cancer Center. , The link between persistent inflammation ... high-grade prostate cancer those with a Gleason score ... the most aggressive and rapidly growing prostate cancers. , ...
(Date:4/17/2014)... of Experimental Biology and Medicine a ... and Paul Kenis in the Institute of Genomic ... of Illinois Urbana-Champaign describe their recent work on ... variety of cell functions including energy metabolism, signaling, ... in regulating normal cellular behavior, redox status has ...
(Date:4/17/2014)... Northwestern University synthetic biology team has created a ... programmable therapeutics that could travel the body and ... , Engineering cell-based, biological devices that monitor and ... clinical synthetic biology. However, no existing technology enabled ... patient,s physiological state and respond in a customized ...
(Date:4/17/2014)... one in five infants in the United States annually ... several months after birth. Research into probiotic use for ... April 1, 2014 issue of the British Medical ... "Probiotics and Infant Colic," concluding that the use of ... did not reduce crying or fussing in infants ...
Breaking Medicine News(10 mins):Health News:Scientists discover brain's anti-distraction system 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3Health News:Live cell imaging reveals distinct alterations of subcellular glutathione potentials 2Health News:Building 'smart' cell-based therapies 2Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2
... research into diseases and treatments, experts say , FRIDAY, ... first detailed map of the human epigenome, gaining greater ... the past, we,ve been limited to viewing small snippets ... the Genomic Analysis Laboratory at the Salk Institute for ...
... physicians will be using electronic prescribing and other health ... million federal grant secured by U.S. Senator Patrick Leahy. ... Technology Leaders, Inc. (VITL), will provide incentives to physicians ... In June, Vermont was cited by Surescripts as the ...
... Avon Foundation for Women is marking Breast Cancer Awareness ... tributes. Throughout October, the Foundation will call attention to ... and raise millions of dollars for the breast cancer ... of fundraising products, Avon Walks for Breast Cancer, and ...
... founding a new publication, the Critical Ultrasound ... as the official publication of WINFOCUS (World Interactive ... will be published in October 2009. ... for clinicians and health professionals using point-of-care ultrasound ...
... ... ... -- While most Canadians have brushed aside worries about H1N1, officials say that the ... West is keeping its students up-to-date with current information about the disease and preventative ...
... off disease and decline, study finds, , FRIDAY, Oct. ... retirement may be surprising: work. , Retirees who continue ... likely to experience physical decline and disease, new U.S. ... and Retirement Study, researchers analyzed six years of information ...
Cached Medicine News:Health News:Scientists Provide First Map of Complete Human Epigenome 2Health News:Leahy Secures Funds to Support Adoption of Electronic Prescribing in Vermont 2Health News:Leahy Secures Funds to Support Adoption of Electronic Prescribing in Vermont 3Health News:Leahy Secures Funds to Support Adoption of Electronic Prescribing in Vermont 4Health News:Leahy Secures Funds to Support Adoption of Electronic Prescribing in Vermont 5Health News:Photos: Avon Foundation for Women Celebrates Breast Cancer Awareness Month 2Health News:Photos: Avon Foundation for Women Celebrates Breast Cancer Awareness Month 3Health News:Springer and WINFOCUS found new journal 2Health News:Schools Still on Alert for H1N1 Outbreaks 2Health News:For a Healthier Retirement, Work a Little 2Health News:For a Healthier Retirement, Work a Little 3
... the proven electrophoretic transfer apparatus incorporating state-of-the-art plate ... design allows for a very close positioning of ... voltage power source such as a battery charger, ... is exceptionally rapid and exact electrophoretic transfer. ...
... 2 gel holder cassettes, 4 fiber pads, ... buffer chamber, lid with cables, and instructions. ... of Bio-Rad's modular mini electrophoresis system (see ... of mini gels. Its modular electrode assembly ...
... Includes: 2 gel holder ... power cables, fiber pads, blot ... cm). The Trans-Blot transfer cell, ... power supply, performs efficient, high-intensity ...
... running Criterion precast gels and Criterion ... fit for use with the incredible ... Criterion blotter combines excellent blotting efficiency ... system and the ease-of-use of the ...
Medicine Products: